<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>ERGOLOID MESYLATES - Naturopathic Formulary Report</title>
    <style>
        body {
            font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif;
            max-width: 1000px;
            margin: 30px auto;
            padding: 40px;
            line-height: 1.6;
            color: #333;
            background-color: #fafafa;
        }
        
        .container {
            background-color: white;
            padding: 40px;
            border-radius: 10px;
            box-shadow: 0 2px 10px rgba(0,0,0,0.1);
        }
        
        h1 {
            color: #2c5282;
            font-size: 2.2em;
            margin-bottom: 10px;
            border-bottom: 3px solid #2c5282;
            padding-bottom: 15px;
        }
        
        h2 {
            color: #2d3748;
            font-size: 1.4em;
            margin-top: 30px;
            margin-bottom: 15px;
            border-left: 4px solid #4299e1;
            padding-left: 15px;
        }
        
        h3 {
            color: #4a5568;
            font-size: 1.2em;
            margin-top: 25px;
            margin-bottom: 10px;
        }
        
        .metadata {
            background: linear-gradient(135deg, #f1f5f9 0%, #e2e8f0 100%);
            color: #1a202c;
            padding: 25px;
            margin: 25px 0;
            border-radius: 8px;
            box-shadow: 0 4px 6px rgba(0,0,0,0.1);
            border: 1px solid #cbd5e0;
        }
        
        .metadata h3 {
            color: #1a202c;
            margin-top: 0;
            font-size: 1.3em;
        }
        
        .category-tags {
            font-size: 1.1em;
            line-height: 1.8;
            margin: 10px 0;
        }
        
        .evidence-strength {
            display: inline-block;
            padding: 5px 15px;
            border-radius: 20px;
            font-weight: bold;
            margin-top: 10px;
        }
        
        .evidence-high { background-color: #48bb78; color: white; }
        .evidence-medium { background-color: #ed8936; color: white; }
        .evidence-low { background-color: #ecc94b; color: #2d3748; }
        .evidence-none { background-color: #a0aec0; color: white; }
        .evidence-welldocumented { background-color: #48bb78; color: white; }
        .evidence-documented { background-color: #ed8936; color: white; }
        .evidence-limited { background-color: #ecc94b; color: #2d3748; }
        
        .report-content {
            font-size: 14px;
            line-height: 1.7;
            color: #2d3748;
            margin-top: 30px;
        }
        
        .report-content p {
            margin-bottom: 15px;
        }
        
        .report-content ul, .report-content ol {
            margin: 15px 0;
            padding-left: 30px;
        }
        
        .report-content li {
            margin-bottom: 8px;
        }
        
        .report-content blockquote {
            border-left: 4px solid #cbd5e0;
            margin: 20px 0;
            padding-left: 20px;
            color: #4a5568;
            font-style: italic;
        }
        
        .report-content code {
            background-color: #f7fafc;
            padding: 2px 6px;
            border-radius: 3px;
            font-family: 'Monaco', 'Consolas', monospace;
        }
        
        @media (max-width: 768px) {
            body {
                margin: 15px;
                padding: 20px;
            }
            .container {
                padding: 25px;
            }
            h1 {
                font-size: 1.8em;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ERGOLOID MESYLATES</h1>
        
        <div class="metadata">
            <h3>Natural Connection Categories</h3>
            <div class="category-tags"><span style="color: #2E8B57; font-weight: bold;">Direct Natural</span>, <span style="color: #4682B4; font-weight: bold;">Semi-Synthetic</span>, <span style="color: #9370DB; font-weight: bold;">Structural Analog</span>, <span style="color: #FF6347; font-weight: bold;">Natural Pathways</span>, <span style="color: #DAA520; font-weight: bold;">Natural Processes</span></div>
            
            <h3>Evidence Strength</h3>
            <span class="evidence-strength evidence-welldocumented">Well-documented</span>
            
            <h3>Formulary Status</h3>
            <span class="formulary-badge" style="background-color: #fd7e14; color: white; padding: 8px 16px; border-radius: 20px; font-weight: bold; font-size: 0.9em; display: inline-block; margin-top: 10px;">üîÑ TARGET FOR MODERNIZATION</span>
        </div>
        
        <div class="report-content">
            <p>
# Naturopathic Formulary Medication Evaluation Protocol<br>
# Objective: Comprehensive assessment of natural derivation and therapeutic alignment<br>
</p>
<p>
For <strong>ERGOLOID MESYLATES</strong>:<br>
</p>
<p>
## 1. NATURAL DERIVATION ASSESSMENT<br>
</p>
<p>
### Source Investigation<br>
Ergoloid mesylates (also known as dihydroergotoxine mesylate) is a mixture of three dihydrogenated ergot alkaloid derivatives: dihydroergocornine, dihydroergocristine, and dihydroergocryptine. These compounds are semi-synthetic derivatives of naturally occurring ergot alkaloids found in the fungus Claviceps purpurea, which parasitizes rye and other grains. The parent ergot alkaloids have been used historically in traditional medicine for obstetric purposes and other therapeutic applications. The natural ergot alkaloids are chemically modified through hydrogenation to reduce their vasoconstrictor properties while maintaining their beneficial neurotropic effects.<br>
</p>
<p>
### Structural Analysis<br>
The ergoloid mesylates retain the core ergoline ring structure of the naturally occurring ergot alkaloids but with hydrogenation at specific positions (9,10-dihydro derivatives). This modification maintains structural similarity to the natural compounds while improving their safety profile. The ergoline structure is also related to naturally occurring neurotransmitters and shares functional groups with dopamine, norepinephrine, and serotonin. The compounds maintain the indole ring system found in many natural alkaloids and endogenous compounds like tryptophan and serotonin.<br>
</p>
<p>
### Biological Mechanism Evaluation<br>
Ergoloid mesylates interact with multiple endogenous receptor systems including alpha-adrenergic, dopaminergic, and serotonergic receptors. They demonstrate partial agonist activity at various receptor subtypes involved in neurotransmission and cerebrovascular regulation. The compounds enhance cellular metabolism and oxygen utilization in neural tissues, supporting natural neuronal function and potentially facilitating endogenous neuroprotective mechanisms.<br>
</p>
<p>
### Natural System Integration (Expanded Assessment)<br>
The medication targets naturally occurring neurotransmitter receptors and enhances endogenous metabolic processes in neural tissue. It works within evolutionarily conserved neurotransmitter systems and may help restore cerebrovascular homeostasis in age-related cognitive decline. The compounds support natural cellular energy metabolism and may facilitate endogenous repair mechanisms in neural tissue. By improving cerebral circulation and cellular metabolism, they may help maintain natural cognitive function and potentially reduce the need for more invasive interventions in mild cognitive impairment.<br>
</p>
<p>
## 2. THERAPEUTIC CONTEXT<br>
</p>
<p>
### Mechanism of Action<br>
Ergoloid mesylates function through multiple mechanisms including alpha-adrenergic receptor blockade, partial dopaminergic and serotonergic activity, and enhancement of cellular metabolism. They improve cerebral blood flow, increase neuronal metabolism, and may enhance neurotransmitter function. The compounds demonstrate neuroprotective properties and may stabilize neuronal membranes while improving oxygen and glucose utilization in brain tissue.<br>
</p>
<p>
### Clinical Utility<br>
Primary therapeutic application is for symptoms of mild to moderate dementia and age-related cognitive decline. The medication has been used for improving mental capacity, mood, and self-care in elderly patients with cognitive impairment. It has a relatively favorable safety profile compared to many other neurotropic medications and is typically used as a long-term supportive therapy rather than acute intervention.<br>
</p>
<p>
### Integration Potential<br>
Shows good compatibility with naturopathic approaches to cognitive health, including nutritional support, botanical medicines, and lifestyle interventions. The medication could serve as supportive therapy while implementing comprehensive naturopathic protocols for cognitive wellness. It requires appropriate practitioner knowledge of its mechanisms and potential interactions with other therapeutic modalities.<br>
</p>
<p>
## 3. REGULATORY AND PRECEDENT CONTEXT<br>
</p>
<p>
### Current Status<br>
Ergoloid mesylates is FDA-approved but carries limitations regarding its clinical efficacy claims. The FDA has required manufacturers to demonstrate efficacy for specific cognitive enhancement claims, and its approval status has been somewhat controversial. It remains available as a prescription medication but with restricted labeling regarding cognitive benefits.<br>
</p>
<p>
### Comparable Medications<br>
Other ergot-derived compounds and neurotropic medications have precedent in various formularies. The natural origin from fungal sources provides some parallel to other naturally-derived medications already accepted in integrative medicine practices.<br>
</p>
<p>
## 4. EVIDENCE DOCUMENTATION<br>
</p>
<p>
### Primary Sources Consulted<br>
DrugBank database, PubMed literature review, FDA prescribing information, PubChem compound database, and peer-reviewed publications on ergot alkaloids and their therapeutic applications. Historical literature on ergot alkaloid use and pharmacological studies of cerebral metabolism enhancement.<br>
</p>
<p>
### Key Findings<br>
Clear natural derivation from ergot fungus alkaloids, documented interaction with endogenous neurotransmitter systems, evidence of metabolic enhancement in neural tissue, and integration with natural physiological processes involved in cerebrovascular regulation and neuronal function.<br>
</p>
<p>
## 5. COMPREHENSIVE ASSESSMENT<br>
</p>
<p>
<strong>ERGOLOID MESYLATES</strong><br>
</p>
<p>
<strong>Evidence Categories Present:</strong><br>
‚òë Direct natural source<br>
‚òë Semi-synthetic from natural precursor<br>
‚òë Structural analog of natural compound<br>
‚òê Endogenous compound or replacement<br>
‚òê Biosynthetic/fermentation product<br>
‚òë Works through natural pathways/receptors<br>
‚òë Facilitates natural physiological processes<br>
‚òê No identified natural connection<br>
</p>
<p>
<strong>Natural Derivation Assessment:</strong><br>
Ergoloid mesylates demonstrates clear natural derivation as semi-synthetic derivatives of ergot alkaloids from Claviceps purpurea fungus. The compounds maintain the essential ergoline structure of the parent natural alkaloids while being chemically modified to improve safety and therapeutic index.<br>
</p>
<p>
<strong>Structural/Functional Relationships:</strong><br>
The ergoline ring structure shows significant similarity to naturally occurring neurotransmitters including serotonin, dopamine, and norepinephrine. The indole ring system is found throughout natural alkaloids and endogenous human compounds. Functional similarity to natural neurotransmitters enables receptor interaction.<br>
</p>
<p>
<strong>Biological Integration:</strong><br>
The medication integrates with endogenous neurotransmitter systems through interaction with alpha-adrenergic, dopaminergic, and serotonergic receptors. It enhances natural cellular metabolic processes and supports endogenous mechanisms of neuronal function and cerebrovascular regulation.<br>
</p>
<p>
<strong>Natural System Interface:</strong><br>
Works within naturally occurring neurotransmitter pathways and enhances endogenous metabolic processes in neural tissue. Supports natural cerebrovascular function and may facilitate the body's own mechanisms for maintaining cognitive function during aging processes.<br>
</p>
<p>
<strong>Safety and Therapeutic Profile:</strong><br>
Generally well-tolerated with mild side effects. Represents a less invasive approach to supporting cognitive function compared to many pharmaceutical alternatives. Long-term use appears relatively safe with appropriate monitoring.<br>
</p>
<p>
<strong>Documentation Quality:</strong><br>
</p>
<ul><li>Number of sources confirming natural connection: 4</li>
<li>Number of sources documenting system integration: 5</li>
<li>Strength of evidence: Well-documented</li>
<li>Conflicting information noted: Yes - regarding clinical efficacy claims and FDA approval status</li></ul>
<p>
<strong>Summary of Findings:</strong><br>
Ergoloid mesylates demonstrates strong natural derivation credentials as semi-synthetic derivatives of naturally occurring ergot alkaloids. The compounds maintain structural relationships to natural neurotransmitters and integrate well with endogenous receptor systems and metabolic processes. While clinical efficacy evidence has limitations, the natural derivation and biological integration with endogenous systems support consideration for naturopathic formulary inclusion.<br>
</p>
<p>
<strong>Relevant Citations:</strong><br>
</p>
<p>
1. DrugBank Online. "Ergoloid mesylate" DrugBank Accession Number DB01049. University of Alberta. Available at: https://go.drugbank.com/drugs/DB01049. Accessed 2024.<br>
</p>
<p>
2. Olin, J., Schneider, L., Novit, A., Luczak, S. "Hydergine for dementia." Cochrane Database of Systematic Reviews 2001, Issue 2. Art. No.: CD000359. DOI: 10.1002/14651858.CD000359.<br>
</p>
<p>
3. PubChem. "Dihydroergotoxine mesylate" PubChem CID 44583. National Center for Biotechnology Information. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/44583.<br>
</p>
<p>
4. Rehman, H.U. "Ergoloid mesylates (Hydergine) in the treatment of dementia: Current perspectives." Clinical Interventions in Aging 2008;3(4):615-624.<br>
</p>
<p>
5. FDA. "Ergoloid mesylates tablets and oral solution prescribing information." Multiple manufacturers. Various approval dates with labeling updates through 2020.<br>
</p>
<p>
6. Schneider LS, Olin JT. "Overview of clinical trials of hydergine in dementia." Archives of Neurology 1994;51(8):787-798.<br>
</p>
<p>
7. Winblad B, Fioravanti M, Dolezal T, et al. "Therapeutic use of nicergoline." Clinical Drug Investigation 2008;28(9):533-552.<br>
</p>
        </div>
    </div>
</body>
</html>